Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 235Lung Neoplasms 106Ovarian Neoplasms 81Breast Neoplasms 81Fallopian Tube Neoplasms 51Small Cell Lung Carcinoma 42Neoplasms 41Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 31Head and Neck Neoplasms 25Adenocarcinoma of Lung 25Parkinson Disease 4, Autosomal Dominant Lewy Body 24Carcinoma 23Neoplasm Metastasis 20Carcinoma, Ovarian Epithelial 18Melanoma 14Lymphoma, Large B-Cell, Diffuse 14Carcinoma, Squamous Cell 14Brain Neoplasms 14Prostatic Neoplasms 13Recurrence 12Lymphoma 12Endometrial Neoplasms 12Adenocarcinoma, Bronchiolo-Alveolar 12Esophageal Neoplasms 11Lymphoma, Non-Hodgkin 10Hodgkin Disease 10Brenner Tumor 10Urinary Bladder Neoplasms 9Central Nervous System Neoplasms 9

Interventions

ganitumab 2conatumumab 1cixutumumab 1Paclitaxel 1Lapatinib 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Insulin-Like Growth Factor I, Resistance To × Carboplatin × Clear all
NCT00807612 2024-09-25

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

NantCell, Inc.

Phase 1/2 Terminated
15 enrolled 11 charts

Insulin-Like Growth Factor I, Resistance To

Data powered by HemOnc (CC BY 4.0) Colophon âš¡